Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis

被引：0
|
作者：
Krueger, J. G. [1 ]
Garcet, S. [1 ]
Cheng, J. [2 ]
Kumar, S. [3 ]
Tang, J. [3 ]
Blau, J. [2 ]
Zhao, Y. [2 ]
Zhang, W. [2 ]
Saha, B. [2 ]
Arunachalam, V. [3 ]
Heap, G. A. [2 ]
Thakker, P. [2 ]
Choudhury, A. [2 ]
机构：
[1] Rockefeller Univ, Lab Invest Dermatol, New York, NY USA
[2] Takeda Pharmaceut Int Co, Gastrointestinal & Inflammat Therapeut Unit, Cambridge, MA USA
[3] Takeda Pharmaceut Int Co, Gastrointestinal & Inflammat Therapeut Unit, San Diego, CA USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2024年 / 144卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
265
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [21] Potent and Selective Tyk2 Inhibitor Highly Efficacious in Rodent Models of Inflammatory Bowel Disease and Psoriasis
    Miao, Wenyan
    Masse, Craig
    Greenwood, Jeremy
    Kapeller, Rosana
    Westlin, William
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [22] Exposure-Response Modeling of an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, BMS-986165, for Pain Visual Analog Scale Score, in Patients with Psoriasis and Musculoskeletal Symptoms
    Shen, Jun
    Chimalakonda, Anjaneya
    Nowak, Miroslawa
    Throup, John
    Banerjee, Subhashis
    Girgis, Ihab
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [23] Influence of Patient Baseline Characteristics on Zasocitinib (TAK-279) Efficacy, a Selective Oral Tyrosine Kinase 2 Inhibitor: A Randomized Phase 2b Trial in Psoriatic Arthritis
    Eder, Lihi
    Muensterman, Elena
    van der Heijde, Desiree
    Kivitz, Alan
    Trivedi, Mona
    Hong, Ting
    Rehman, Muhammad
    Weng, Haoling
    Chen, Jingjing
    Baraliakos, Xenofon
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4718 - 4720
  • [24] Selective inhibition of tyrosine kinase 2 (TYK2) improves molecular, cellular, and clinical biomarkers associated with efficacy in psoriasis without impacting Janus kinase (JAK) pathways
    Catlett, Ian
    Hu, Sarah
    Banerjee, Subhashis
    Gordon, Kenneth
    Kruger, James
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 24 - 24
  • [25] An oral, selective tyrosine kinase 2 (TYK2) inhibitor, BMS-986165, improves quality of life (QoL) in psoriasis (PsO): results from a Phase 2 study
    Thaci, Diamant
    Papp, Kim Alexander
    Gordon, Kenneth
    Morita, Akimichi
    Gooderham, Melinda
    Foley, Peter
    Alemao, Evo
    Kisa, Renata
    Elbez, Yedid
    Ren, Haobo
    Banerjee, Subhashis
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 24 - 25
  • [26] A Novel, Oral, Allosteric Inhibitor of Tyrosine Kinase 2 (TYK2) Demonstrates In Vitro Potency, Selectivity, and In Vivo Efficacy in Mouse Models of Psoriasis
    Hussein, Razika
    Tsuruda, Pamela
    Mortezaei, Shahab
    Ferdyan, Nicky
    Wegerski, Christopher
    Srinivasan, Karthik
    Hirst, Gavin
    Mozaffarian, Neelufar
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1848 - 1849
  • [27] Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
    Wrobleski, Stephen T.
    Moslin, Ryan
    Lin, Shuqun
    Zhang, Yanlei
    Spergel, Steven
    Kempson, James
    Tokarski, John S.
    Strnad, Joann
    Zupa-Fernandez, Adriana
    Cheng, Lihong
    Shuster, David
    Gillooly, Kathleen
    Yang, Xiaoxia
    Heimrich, Elizabeth
    McIntyre, Kim W.
    Chaudhry, Charu
    Khan, Javed
    Ruzanov, Max
    Tredup, Jeffrey
    Mulligan, Dawn
    Xie, Dianlin
    Sun, Huadong
    Huang, Christine
    D'Arienzo, Celia
    Aranibar, Nelly
    Chiney, Manoj
    Chimalakonda, Anjaneya
    Pitts, William J.
    Lombardo, Louis
    Carter, Percy H.
    Burke, James R.
    Weinstein, David S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (20) : 8973 - 8995
  • [28] BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, does not affect the pharmacokinetics of methotrexate in healthy subjects
    Chimalakonda, A.
    Jones, J., III
    Dockens, R.
    Throup, J.
    Banerjee, S.
    Girgis, I.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S437 - S438
  • [29] Evaluation of pharmacology and clinical response to TYK2/JAK1 kinase inhibitor, PF-06700841, in patients with plaque psoriasis
    Page, Karen M.
    Zhang, Weidong
    Scaramozza, Matthew
    Suprun, Maria
    Suarez-Farinas, Mayte
    Fuentes-Duculan, Judilyn
    James, G. Krueger
    Winkle, Peter J.
    Peeva, Elena
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB130 - AB130
  • [30] BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS
    Fitzgerald, O.
    Gladman, D. D.
    Mease, P. J.
    Ritchlin, C. T.
    Smolen, J. S.
    Gao, L.
    Hu, S.
    Nowak, M.
    Banerjee, S.
    Catlett, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 215 - 216
12345